<table border="0" cellpadding="0" cellspacing="2" id="t10496122" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Established and Potential Drug Interactions: Use
With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug
Interaction Established Drug Interactions: See Clinical Pharmacology
(12.3), Table 5 for Magnitude of Interaction.</caption>
<colgroup>
<col valign="top" width="40%"></col>
<col valign="top" width="25%"></col>
<col valign="top" width="35%"></col>
</colgroup>
<tfoot>
<tr>
<td colspan="3" stylecode="Botrule">
<content stylecode="bold">* </content>The interaction
between VIRAMUNE and the drug was evaluated in a clinical study. 
All other drug interactions shown are predicted.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Drug Name</content>
</td>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Effect on Concentration of <br/>Nevirapine or Concomitant Drug</content>
</td>
<td stylecode="Toprule Botrule" valign="top">
<content stylecode="bold">Clinical Comment</content>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule">
<content stylecode="bold">HIV Antiviral Agents:
Protease Inhibitors (PIs)</content>
</td>
</tr>
<tr>
<td stylecode="Toprule">Atazanavir/Ritonavir*<br/>
<br/>
</td>
<td stylecode="Toprule">↓ Atazanavir<br/>↑ Nevirapine<br/>
<br/>
</td>
<td stylecode="Toprule" valign="top">Do not co-administer nevirapine with
atazanavir because nevirapine substantially decreases atazanavir exposure
and there is a potential risk for nevirapine-associated toxicity due
to increased nevirapine exposures.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">Fosamprenavir*<br/>
<br/>
</td>
<td stylecode="Toprule">↓ Amprenavir<br/>↑ Nevirapine<br/>
<br/>
</td>
<td stylecode="Toprule">Co-administration of nevirapine and fosamprenavir
without ritonavir is not recommended.<br/>
<br/>
</td>
</tr>
<tr>
<td>Fosamprenavir/Ritonavir*<br/>
<br/>
</td>
<td>↓ Amprenavir<br/>
<br/>↑ Nevirapine<br/>
<br/>
</td>
<td>No dosing adjustments are required when nevirapine is co-administered
with 700/100 mg of fosamprenavir/ritonavir twice daily.  The combination
of nevirapine administered with fosamprenavir/ritonavir once daily
has not been studied.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">Indinavir*<br/>
<br/>
</td>
<td stylecode="Toprule">↓ Indinavir<br/>
<br/>
</td>
<td stylecode="Toprule">The appropriate doses of this combination of indinavir
and nevirapine with respect to efficacy and safety have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule" valign="top">Lopinavir/Ritonavir*<br/>
<br/>
</td>
<td stylecode="Toprule" valign="top">↓Lopinavir<br/>
<br/>
</td>
<td stylecode="Toprule">Dosing in adult patients:<br/>
<br/>A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice
daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended
when used in combination with nevirapine.  Neither lopinavir/ritonavir
tablets nor oral solution should be administered once daily in combination
with nevirapine.<br/>
<br/>Dosing in pediatric patients:<br/>
<br/>Please refer to the Kaletra<sup>®</sup> prescribing information for dosing recommendations based on body
surface area and body weight.  Neither lopinavir/ritonavir tablets
nor oral solution should be administered once daily in combination
with nevirapine.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">Nelfinavir*<br/>
<br/>
</td>
<td stylecode="Toprule">↓Nelfinavir M8 Metabolite<br/>↓Nelfinavir
C<sub>min</sub>
<br/>
<br/>
</td>
<td stylecode="Toprule">The appropriate doses of the combination of nevirapine
and nelfinavir with respect to safety and efficacy have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Saquinavir/ritonavir<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">The interaction between nevirapine and
saquinavir/ritonavir has not been evaluated<br/>
<br/>
</td>
<td stylecode="Toprule Botrule" valign="top">The appropriate doses of the
combination of nevirapine and saquinavir/ritonavir with respect to
safety and efficacy have not been established. <br/>
<br/>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule">
<content stylecode="bold">HIV Antiviral Agents:
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</content>
</td>
</tr>
<tr>
<td stylecode="Toprule">Efavirenz*<br/>
<br/>
</td>
<td stylecode="Toprule">↓ Efavirenz<br/>
<br/>
</td>
<td stylecode="Toprule">The appropriate doses of these combinations with
respect to safety and efficacy have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Botrule">Delavirdine<br/>Etravirine<br/>Rilpivirine<br/>
<br/>
</td>
<td stylecode="Botrule"> </td>
<td stylecode="Botrule">Plasma concentrations may be altered.  Nevirapine
should not be coadministered with another NNRTI as this combination
has not been shown to be beneficial.<br/>
<br/>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule">
<content stylecode="bold">Hepatitis C Antiviral
Agents</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Boceprevir<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">Plasma concentrations of boceprevir may
be decreased due to induction of CYP3A4/5 by nevirapine.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule" valign="top">Nevirapine and boceprevir
should not be coadministered because decreases in boceprevir plasma
concentrations may result in a reduction in efficacy.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Telaprevir<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">Plasma concentrations of telaprevir may
be decreased due to induction of CYP3A4 by nevirapine and plasma concentrations
of nevirapine may be increased due to inhibition of CYP3A4 by telaprevir.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule" valign="top">Nevirapine and telaprevir
should not be coadministered because changes in plasma concentrations
of nevirapine, telaprevir, or both may result in a reduction in telaprevir
efficacy or an increase in nevirapine-associated adverse events.<br/>
<br/>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Toprule Botrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr>
<td stylecode="Toprule">
<content stylecode="bold">Analgesics:</content>
</td>
<td stylecode="Toprule"> </td>
<td stylecode="Toprule"> </td>
</tr>
<tr>
<td stylecode="Botrule" valign="top">Methadone*<br/>
<br/>
</td>
<td stylecode="Botrule" valign="top">↓ Methadone<br/>
<br/>
</td>
<td stylecode="Botrule" valign="top">Methadone levels were decreased;
increased dosages may be required to prevent symptoms of opiate withdrawal.
 Methadone-maintained patients beginning nevirapine therapy should
be monitored for evidence of withdrawal and methadone dose should
be adjusted accordingly.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">
<content stylecode="bold">Antiarrhythmics: </content>
</td>
<td stylecode="Toprule"> </td>
<td stylecode="Toprule"> </td>
</tr>
<tr>
<td stylecode="Botrule">Amiodarone, disopyramide, lidocaine<br/>
<br/>
</td>
<td stylecode="Botrule">Plasma concentrations may be decreased.<br/>
<br/>
</td>
<td stylecode="Botrule">Appropriate doses for this combination have
not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">
<content stylecode="bold">Antibiotics:</content>
</td>
<td stylecode="Toprule"> </td>
<td stylecode="Toprule"> </td>
</tr>
<tr>
<td>Clarithromycin*<br/>
<br/>
</td>
<td>↓ Clarithromycin<br/>↑ 14-OH clarithromycin<br/>
<br/>
</td>
<td>Clarithromycin exposure was significantly decreased by nevirapine;
however, 14-OH metabolite concentrations were increased.  Because
clarithromycin active metabolite has reduced activity against <content stylecode="italics">Mycobacterium avium-intracellulare complex</content>, overall activity
against this pathogen may be altered.  Alternatives to clarithromycin,
such as azithromycin, should be considered.<br/>
<br/>
</td>
</tr>
<tr>
<td>Rifabutin*<br/>
<br/>
</td>
<td>↑ Rifabutin<br/>
<br/>
</td>
<td>Rifabutin and its metabolite concentrations were moderately increased.
 Due to high intersubject variability, however, some patients may
experience large increases in rifabutin exposure and may be at higher
risk for rifabutin toxicity.  Therefore, caution should be used in
concomitant administration.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Botrule">Rifampin*<br/>
<br/>
</td>
<td stylecode="Botrule">↓ Nevirapine<br/>
<br/>
</td>
<td stylecode="Botrule">Nevirapine and rifampin should not be administered
concomitantly because decreases in nevirapine plasma concentrations
may reduce the efficacy of the drug.  Physicians needing to treat
patients co-infected with tuberculosis and using a nevirapine-containing
regimen may use rifabutin instead.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>Carbamazepine, clonazepam, ethosuximide<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations of nevirapine
and the anticonvulsant may be decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule" valign="top">
<br/>Use with caution
and monitor virologic response and levels of anticonvulsants.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">
<content stylecode="bold">Antifungals:</content>
</td>
<td stylecode="Toprule"> </td>
<td stylecode="Toprule"> </td>
</tr>
<tr>
<td>Fluconazole*<br/>
<br/>
</td>
<td>↑Nevirapine<br/>
<br/>
</td>
<td>Because of the risk of increased exposure to nevirapine, caution
should be used in concomitant administration, and patients should
be monitored closely for nevirapine-associated adverse events.<br/>
<br/>
</td>
</tr>
<tr>
<td>Ketoconazole*<br/>
<br/>
</td>
<td>↓ Ketoconazole<br/>
<br/>
</td>
<td>Nevirapine and ketoconazole should not be administered concomitantly
because decreases in ketoconazole plasma concentrations may reduce
the efficacy of the drug.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Botrule">Itraconazole<br/>
<br/>
</td>
<td stylecode="Botrule">↓ Itraconazole<br/>
<br/>
</td>
<td stylecode="Botrule">Nevirapine and itraconazole should not be administered
concomitantly due to potential decreases in itraconazole plasma concentrations
that may reduce efficacy of the drug.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Antithrombotics:</content>
<br/>Warfarin<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
increased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Potential effect on anticoagulation.
Monitoring of anticoagulation levels is recommended.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Calcium channel blockers:</content>
<br/>Diltiazem, nifedipine, verapamil<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Appropriate doses for these
combinations have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Cancer chemotherapy:</content>
<br/>Cyclophosphamide<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Appropriate doses for this
combination have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Ergot alkaloids:</content>
<br/>Ergotamine<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Appropriate doses for this
combination have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Immunosuppressants:</content>
<br/>Cyclosporine, tacrolimus, sirolimus<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Appropriate doses for these
combinations have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Motility agents:</content>
<br/>Cisapride<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Appropriate doses for this
combination have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Opiate agonists:</content>
<br/>Fentanyl<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Plasma concentrations may be
decreased.<br/>
<br/>
</td>
<td stylecode="Toprule Botrule">
<br/>Appropriate doses for this
combination have not been established.<br/>
<br/>
</td>
</tr>
<tr>
<td stylecode="Toprule">
<content stylecode="bold">Oral contraceptives:</content>
</td>
<td stylecode="Toprule"> </td>
<td stylecode="Toprule"> </td>
</tr>
<tr>
<td stylecode="Botrule">Ethinyl estradiol and Norethindrone*<br/>
<br/>
</td>
<td stylecode="Botrule">↓ Ethinyl estradiol<br/>↓ Norethindrone<br/>
<br/>
</td>
<td stylecode="Botrule">Despite lower ethinyl estradiol and norethindrone
exposures when coadministered with nevirapine, literature reports
suggest that nevirapine has no effect on pregnancy rates among HIV-infected
women on combined oral contraceptives. When coadministered with VIRAMUNE,
no dose adjustment of ethinyl estradiol or norethindrone is needed
when used in combination for contraception.<br/>
<br/>When these oral contraceptives are used for hormonal regulation
during VIRAMUNE therapy, the therapeutic effect of the hormonal therapy
should be monitored.</td>
</tr>
</tbody>
</table>